Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > Globe Newswire

<< Previous

Bullboard Posts

Next >>

Comment by narmacon Jan 18, 2021 5:30pm

328 Views

Post# 32322670

RE:RE:RE:RE:Globe Newswire

aaacccchhhh,,iit should not be a surprise,,,,option B or C would fit right in with DMcC business prowess,,,,,,,,,wait a year with his thumb in his bum and be left with the paper bag on fire on his doorstep,
I think an internal power struggle from the major insiders are the reason no deal is done,,,and we have been in limbo for the past year+.
Just an opinion based on not being able to access tea leaves for a good read!!

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity